On November 7, during the 7th China International Import Expo, Abbott Laboratories announced the launch of its women's health new drug Femylene in China. The drug is used to treat symptoms of estrogen deficiency in women after menopause for at least 12 months. It is reportedly the first domestic continuous combination formulation containing estrogen and progesterone components selected by authoritative guidelines.